dr reddys laboratories
Jump to
1798 Results Found
  • Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan Mar 05, 2021 01:34 PM IST

    Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

    Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated March 04, 2021.

  • Dr Reddy's launches stomach, esophagus problems treatment drug in the US Feb 22, 2021 12:34 PM IST

    Dr Reddy's launches stomach, esophagus problems treatment drug in the US

    The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA).

  • Dr Reddy's begins process to obtain emergency use authorisation for Sputnik V Feb 19, 2021 06:30 PM IST

    Dr Reddy's begins process to obtain emergency use authorisation for Sputnik V

    Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia, the statement said.

  • Dr Reddy's launches Fluphenazine Hydrochloride tablets in US Feb 18, 2021 12:05 PM IST

    Dr Reddy's launches Fluphenazine Hydrochloride tablets in US

    The product is a therapeutic equivalent generic version of Prolixin tablets approved by the US Food and Drug Administration (USFDA).

  • Buy Dr Reddy's Laboratories; target of Rs 5200: Dolat Capital Market Feb 09, 2021 11:48 PM IST

    Buy Dr Reddy's Laboratories; target of Rs 5200: Dolat Capital Market

    Dolat Capital Market is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5200 in its research report dated January 31, 2021.

  • Buy Dr Reddy’s Laboratories; target of Rs 6500: Sharekhan Feb 09, 2021 10:52 PM IST

    Buy Dr Reddy’s Laboratories; target of Rs 6500: Sharekhan

    Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated January 29, 2021.

  • Buy Dr. Reddy's Laboratories; target of Rs 5406: Prabhudas Lilladher Feb 08, 2021 03:44 PM IST

    Buy Dr. Reddy's Laboratories; target of Rs 5406: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5406 in its research report dated January 30, 2021.

  • Buy Dr Reddy’s Laboratories; target of Rs 5525: ICICI Direct Feb 04, 2021 05:22 PM IST

    Buy Dr Reddy’s Laboratories; target of Rs 5525: ICICI Direct

    ICICI Direct is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5525 in its research report dated January 30, 2021.

  • Dr Reddys Labs Standalone December 2020 Net Sales at Rs 3,408.20 crore, up 11.96% Y-o-Y Feb 02, 2021 09:22 AM IST

    Dr Reddys Labs Standalone December 2020 Net Sales at Rs 3,408.20 crore, up 11.96% Y-o-Y

  • Dr Reddy's Labs Q3 profit at Rs 20 crore, revenue rises 12% YoY Jan 29, 2021 12:08 PM IST

    Dr Reddy's Labs Q3 profit at Rs 20 crore, revenue rises 12% YoY

    The company said the Q3FY21 PAT was impacted primarily due to the non-recognition of deferred tax assets on impairment.

  • Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus Jan 29, 2021 07:28 AM IST

    Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus

    Brokerage firm Kotak Institutional Equities expects the company's US business to increase by $8 mn quarter-on-quarter (QoQ) to $255 mn, led by the launch of Kuvan.

  • Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher Jan 18, 2021 11:05 PM IST

    Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 12.3 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 4,397.1 crore, according to Prabhudas Lilladher.

  • Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan Jan 13, 2021 01:01 PM IST

    Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

    Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated January 12, 2021.

  • Mumbai airport to handle over half of SII's Covishield vaccine Jan 11, 2021 05:24 PM IST

    Mumbai airport to handle over half of SII's Covishield vaccine

    The Indian government will launch the vaccination drive from January 16, and the transportation of the vaccines may begun from January 11, to ensure a steady supply chain.

  • Serum Institute gets ahead in COVID-19 vaccine, but opportunity still exists for others Jan 06, 2021 09:03 AM IST

    Serum Institute gets ahead in COVID-19 vaccine, but opportunity still exists for others

    Serum Institute alone cannot inoculate the entire population at one go. This leaves enough space for competitor vaccines, provided they succeed in clinical trials

  • Russia will jointly produce Sputnik V vaccine for COVID-19 with India: Russian envoy Nikolay Kudashev Dec 21, 2020 09:22 PM IST

    Russia will jointly produce Sputnik V vaccine for COVID-19 with India: Russian envoy Nikolay Kudashev

    The vaccine was developed by the Gamaleya Research Institute while the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, is investing in the production and promotion of the vaccine abroad.

  • Dr Reddy’s Laboratories shares gain as firm commences clinical trials for Sputnik V vaccine Dec 02, 2020 10:12 AM IST

    Dr Reddy’s Laboratories shares gain as firm commences clinical trials for Sputnik V vaccine

    The clinical trials are being conducted by JSS Medical Research who are the clinical research partner.

  • Buy Dr Reddy's Laboratories; target of Rs 6000: ICICI Direct Nov 04, 2020 09:37 PM IST

    Buy Dr Reddy's Laboratories; target of Rs 6000: ICICI Direct

    ICICI Direct is bullish on Dr Reddy's Laboratories recommended buy rating on the stock with a target price of Rs 6000 in its research report dated October 29, 2020.

  • Accumulate Dr. Reddy’s laboratories; target of Rs 5418 KR Choksey Nov 04, 2020 08:53 PM IST

    Accumulate Dr. Reddy’s laboratories; target of Rs 5418 KR Choksey

    KR Choksey recommended accumulate rating on Dr. Reddy’s laboratories with a target price of Rs 5418 in its research report dated October 30, 2020.

  • Accumulate Dr Reddy's Laboratories; target of Rs 5414: Dolat Capital Market Nov 03, 2020 04:58 PM IST

    Accumulate Dr Reddy's Laboratories; target of Rs 5414: Dolat Capital Market

    Dolat Capital Market recommended accumulate rating on Dr Reddy's Laboratories with a target price of Rs 5414 in its research report dated October 28, 2020.

  • Buy Dr. Reddy's Laboratories; target of Rs 5964: Prabhudas Lilladher Nov 03, 2020 04:36 PM IST

    Buy Dr. Reddy's Laboratories; target of Rs 5964: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5964 in its research report dated October 29, 2020.

  • Dr Reddy's Labs shares jump after Credit Suisse maintains outperform rating, expects earnings momentum to continue Oct 29, 2020 11:18 AM IST

    Dr Reddy's Labs shares jump after Credit Suisse maintains outperform rating, expects earnings momentum to continue

    Credit Suisse is of the view that Q2 was better than expected with strength driven by US sales. Earnings momentum should continue with more limited competition launches.

  • Dr Reddys Labs Consolidated September 2020 Net Sales at Rs 4,910.90 crore, up 2.04% Y-o-Y Oct 29, 2020 10:22 AM IST

    Dr Reddys Labs Consolidated September 2020 Net Sales at Rs 4,910.90 crore, up 2.04% Y-o-Y

  • Dr Reddys Labs Standalone September 2020 Net Sales at Rs 3,345.80 crore, down 2.91% Y-o-Y Oct 29, 2020 09:44 AM IST

    Dr Reddys Labs Standalone September 2020 Net Sales at Rs 3,345.80 crore, down 2.91% Y-o-Y

  • Dr Reddy's plans to complete phase 3 trial of Sputnik V COVID vaccine by March end Oct 28, 2020 09:19 PM IST

    Dr Reddy's plans to complete phase 3 trial of Sputnik V COVID vaccine by March end

    CEO Erez Israeli said the company would begin phase II trials in the next few days

Sections